Elevated concentrations of fecal calprotectin in patients with liver cirrhosis;Erhöhte konzentrationen von fäkalem calprotectin bei patienten mit leberzirrhose

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 36, 2006, Pages 1930-1934

  Yagmur, E ^a   Schnyder, B ^a   Scholten, D ^a   Schirin Sokhan, R ^a   Koch, A ^a   Winograd, R ^a   Gressner, A M ^a   Trautwein, C ^a   Wasmuth, Hermann E ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Calprotectin; Child Pugh score; Inflammation; Liver cirrhosis

Indexed keywords

C REACTIVE PROTEIN; CALPROTECTIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8;

ALCOHOL LIVER CIRRHOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FECES LEVEL; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; FECES; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; LEUKOCYTE L1 ANTIGEN COMPLEX; LIVER CIRRHOSIS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 33749640952     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-949189     Document Type: Article

References (20)

1. Bahr MJ, Manns MP. Function of the immune system in liver cirrhosis. Z Gastroenterol 2001; 39: 601-607
2. Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993; 34: 1357-1363
3. Bundesministerium für Forschung und Gesundheit. Chronische Leberkrankheit und -zirrhose. Baden-Baden, In: Ernährungsabhängige Krankheiten und ihre Kosten. 1993: 200-206
4. Campillo B, Pernet P, Bories PN, Richardet JP, Devanlay M, Aussel C. Intestinal permeability in liver cirrhosis: relationship with severe sepsic complications. Eur J Gastroenterol Hepatol 1999; 11: 755-759
5. Homan C, Christensen E, Schlichting P, Philipsen EK, Graudal NA, Garred P. Ascites fluid and plasma calprotectin concentrations in liver disease. Scand J Gastroenterol 2003; 38: 415-420
6. Homan C, Garred P, Graudal N, Hasselqvist P, Christiansen M, Fagerhol MK, Thomsen AC. Plasma calprotectin: a new prognostic marker of survival in alcohol-induced cirrhosis. Hepatology 1995; 21: 979-985
7. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, Dale I. Functional and clinical aspects of the myelomonocytic protein calprotectin. J Clin Pathol 1997; 50: 113-123
8. Misra V, Misra S, Dwivedi M, Gupta S. Histomorphometric study of portal hypertensive enteropathy. Am J Clin Pathol 1997; 108: 652-657
9. Poullis A, Foster R, Northfield TC, Mendall MA. Review article: faecal markers I the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 675-681
10. Roseth AG, Audland E, Jahnsen J, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterology 1999; 34: 50-54
11. Saitoh O, Sugi K, Kojima K, Matsumoto H, Nakagawa K, Masanobu K, Tanaka S, Teranishi T, Hirata I, Katsu K. Increased prevalence of intestinal inflammation in patients with liver cirrhosis. World J Gastroenterol 1999; 5: 391-396
12. Scandalis N, Archimandritis A, Kastanas K, Spiliadis C, Delis B, Manika Z. Co-Ionic findings in cirrhotics with portal hypertension. A prospective colonoscopic and histological study. J Clin Gastroenterol 1994; 18: 325-329
13. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein. Lancet 1990; 336: 763-765
14. Tam TN, Ng WW, Lee SD. Colonic mucosal changes in patients with liver cirrhosis. Gastrointest Endosc 1995; 42: 408-412
15. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood test in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49: 402-408
16. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjanarson I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22
17. Tibble JA, Sigthorsson G, Foster R, Forgocs I, Bjarnason I. Use of surrogate markers of Inflammation and Rome citeria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-460
18. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghöner A, Vidacek D, Siewert E, Bach J, Geier A, Purucker EA, Gressner AM, Matern S, Lammert F. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005; 42: 195-201
19. Wiest R, Guadalupe G-T. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-433
20. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M. International Ascites Club. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005; 54: 718-725